Abstract
The median age at diagnosis of primary brain cancers in Australia was 55–59 years for males and 60–64 for females in 1999. Low-grade gliomas have a peak incidence in the fourth decade [1]. For high-grade gliomas the peak incidence occurs in the eighth decade. There were 1,369 people, or 6.8 per 100,000, diagnosed with primary brain cancer in 2004, the latest year for which national figures are available [2, 3]. In comparison, approximately 161 new cases of breast cancer and 64 new cases of colon cancer were diagnosed per 100,000 population that year. The Australian Institute of Health and Welfare ranks primary brain cancer as the 14th most common cancer. In the Australian States and Territories, the age-standardized incidence of brain cancer ranged from 6.3 per 100,000 in Western Australia and the Northern Territory to 7.5 per 100,000 in Victoria in 2001 (the most recent year for which State data are available) [4].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Surveillance, Epidemiology and End Results SEER Program. SEER*Stat Database: Incidence—SEER 9 Regs Public-Use, Nov 2003 Sub (1973–2001), 1 April 2004. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch.
AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries). Cancer in Australia: an overview, 2006, No. 37, Cancer series. Canberra: AIHW; 2007.
Australian Institute of Health and Welfare. ACIM (Australian Cancer Incidence and Mortality) Books. Canberra: Australian Institute of Health and Welfare; 2007.
Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer survival in Australia, 2001. Part 1: National summary statistics, 13. Cancer Series No. 18. Canberra: Australian Institute of Health and Welfare; 2001.
Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer in Australia 2001, Cancer Series, vol. No. 28, CAN 23. Canberra: AIHW; 2004.
Access Economics. Cost of cancer in NSW, 15 June 2006. Sydney: Cancer Council NSW.
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215.
Rosenthal MA, Drummond KJ, Dally M, Murphy M, Cher L, Ashley D, et al. Management of glioma in Victoria (1998–2000): retrospective cohort study. Med J Aust. 2006;184:270–3.
Chang SM, Parney IF, Huang W, Anderson FA, Asher AL, Bernstein M, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005;293(5):557–64. Am Med Assoc. Ref Type: Generic.
Frappaz D, Chinot O, Bataillard A, Ben HM, Capelle L, Chanalet S, et al. Standards, options and recommendations 2002 for the management of adult patients with intracranial gliomas (summary report). Bull Cancer. 2003;90:873–86.
Australian Transport Council. Assessing fitness to drive for commercial and private vehicle drivers, and clinical management guidelines, vol. 3. Sydney: Austroads; 2003.
Chiro GD, Brooks A, Kornblith PL, Smith H. Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol. 1984;15:S138–46.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352:987–96.
Mason WP, Del Maestro R, Eisenstat D, Forsyth P, Fulton D, LaperriFre N, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007;14:110.
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–93.
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995;345:1008–12.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this chapter
Cite this chapter
Lehman, M., Barton, M. (2013). Glioma of the Central Nervous System Surveillance Counterpoint: Australia. In: Johnson, F., et al. Patient Surveillance After Cancer Treatment. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-969-7_105
Download citation
DOI: https://doi.org/10.1007/978-1-60327-969-7_105
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-968-0
Online ISBN: 978-1-60327-969-7
eBook Packages: MedicineMedicine (R0)